The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

A therapy at the center of their $22 billion alliance failed to extend survival in a type of lung tumor, leading the ...

Merck (MRK) stock falls as the company withdraws U.S. marketing application for lung cancer therapy HER3-DXd developed with ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Berlin: Bayer has received Priority Review status from the US Food and Drug Administration (FDA) for the investigational ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Ongoing research is focusing on combining cryoablation with immunotherapy to trigger stronger immune responses and redefine ...

Thanks to federally funded cancer research and clinical trials at Johns Hopkins, John Ryan has been able to attend ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified ...